ADMA Biologics Shares Jump 25% on Higher Quarterly Results

ADMA Biologics shares climbed 25% to $13.06 in morning trading after the company reported higher third-quarter revenue and earnings. The gain came even as the stock remained down 15% over the past 12 months.

Today, 19:06· Money Talk· 667 reads

ADMA Biologics Shares Jump 25% on Higher Quarterly Results

Revenue for the quarter reached $141.1 million, up from $134.2 million in the same period a year earlier. ADMA reported earnings of $49.9 million, or 22 cents a share, compared with $36.4 million, or 15 cents a share, a year ago. Adjusted earnings were 23 cents a share.

Revenue from lead product Asceniv rose 31% to $124.7 million. Bivigam generated $15.4 million in revenue.

For fiscal 2026, the company expects revenue of at least $530 million and adjusted earnings of at least $180 million.

ADMA Biologics Shares Jump 25% on Higher Quarterly Results

Comments (0)